Fevertree Drinks (FEVR) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
24 Dec, 2025Executive summary
Achieved 4% constant currency growth in 2024, with strong U.S. and Rest of World performance, and resilience in Europe and the U.K. despite challenging conditions.
Entered a transformational partnership with Molson Coors in the U.S., expected to drive significant revenue growth, operational efficiencies, and brand reach, with guaranteed U.S. profits and lower working capital requirements.
Expanded share buyback program to GBP 100 million for the year, reflecting strong cash generation and balance sheet strength.
Continued to diversify product portfolio, with non-tonic products now comprising almost 30% of U.K. sales and a strong innovation pipeline across alcoholic and non-alcoholic categories.
Maintains #1 premium mixer brand globally, with strong innovation and distribution capabilities.
Financial highlights
FY24 brand revenue reached £364.0m, up 4% at constant currency; total group revenue was £368.5m, up 3% at constant currency.
Adjusted EBITDA increased by 66% year-over-year to £50.7m (margin 13.7%, +530bps YoY), driven by margin recovery and operational improvements.
Gross profit rose 18% to £138.4m, with gross margin improving to 37.5% (+540bps YoY) due to lower glass and freight costs, pricing actions, and procurement efficiencies.
Operating cash flow conversion reached 150%, resulting in a 60% increase in net cash to GBP 96 million.
Incurred GBP 5 million in exceptional costs, mainly related to U.S. bottler exit and advisory fees for the Molson Coors deal.
Outlook and guidance
2025 guidance: low single-digit group revenue growth, with short-term EBITDA impact due to U.S. transition.
2026: double-digit group revenue and EBITDA growth expected as U.S. marketing spend normalizes.
From 2027, uplift in group revenue and EBITDA anticipated as Molson Coors partnership benefits are fully realized, with guaranteed profit element for 2026–2030.
Non-U.S. business expected to deliver further gross margin improvement in 2025, targeting a 200 basis point increase.
Potential U.S. tariffs could impact 2025–2026, but expected to be mitigated from 2027 via local production and profit guarantees.
Latest events from Fevertree Drinks
- FY25 revenue and EBITDA to surpass expectations, with robust US and global growth.FEVR
Trading update29 Jan 2026 - 79% EBITDA growth and 520bps margin gain in H1, with strong US and global share gains.FEVR
H1 202420 Jan 2026 - Molson Coors takes 8.5% stake, US operations, and guarantees royalties for accelerated growth.FEVR
Partnership9 Jan 2026 - US partnership, diversification, and strong cash drive growth; outlook and buybacks positive.FEVR
H1 202512 Sep 2025 - Fever-Tree delivers market share gains and reaffirms full year outlook with global growth.FEVR
Trading Update13 Jun 2025 - Strong US growth, UK leadership, and robust capital returns mark Fever-Tree's 2025 update.FEVR
Trading Update9 Jun 2025